Invuity (IVTY) Rating Reiterated by Northland Securities

Invuity (NASDAQ:IVTY)‘s stock had its “buy” rating reissued by research analysts at Northland Securities in a research report issued to clients and investors on Wednesday. They presently have a $6.00 target price on the medical instruments supplier’s stock. Northland Securities’ price target would suggest a potential upside of 51.90% from the company’s current price.

The analysts wrote, “We would be remiss in not expressing our disappointment, and are lowering our PT to $6.””

Several other research firms have also weighed in on IVTY. Zacks Investment Research lowered Invuity from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Piper Jaffray Companies reissued a “buy” rating and issued a $12.00 target price on shares of Invuity in a research note on Friday, November 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. Invuity currently has an average rating of “Buy” and an average price target of $8.50.

Shares of Invuity (NASDAQ IVTY) traded down $0.55 on Wednesday, hitting $3.95. The stock had a trading volume of 479,800 shares, compared to its average volume of 284,777. The company has a quick ratio of 2.47, a current ratio of 2.90 and a debt-to-equity ratio of 5.39. Invuity has a twelve month low of $3.75 and a twelve month high of $9.70. The firm has a market capitalization of $77.13, a price-to-earnings ratio of -1.60 and a beta of -0.50.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlueCrest Capital Management Ltd acquired a new stake in shares of Invuity during the fourth quarter worth about $139,000. Eversept Partners LLC acquired a new stake in shares of Invuity during the fourth quarter worth about $279,000. CAPROCK Group Inc. raised its position in shares of Invuity by 28.6% during the third quarter. CAPROCK Group Inc. now owns 45,000 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 10,000 shares during the period. OxFORD Asset Management LLP acquired a new stake in shares of Invuity during the second quarter worth about $374,000. Finally, Wells Fargo & Company MN raised its position in shares of Invuity by 987.0% during the fourth quarter. Wells Fargo & Company MN now owns 64,198 shares of the medical instruments supplier’s stock worth $398,000 after purchasing an additional 58,292 shares during the period. 67.57% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/14/invuity-ivty-rating-reiterated-by-northland-securities.html.

About Invuity

Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.

Receive News & Ratings for Invuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply